Retatrutide does it via GLP-1 receptor activation in the gut and CNS
13 This would create a highly differentiated product that solves a real-world clinical problem while leveraging a streamlined regulatory path
Did they drop coverage for everyone
Coverage: Medicaid coverage policies for GLP-1 medications were obtained from KFF.org
Both candidates are designed to move beyond single-pathway GLP-1 therapy, but they take very different routes: CagriSema combines an amylin analog with semaglutide, while Retatrutide compresses GIP, GLP-1, and glucagon agonism into one investigational peptide
This is an investigational oral medicine for inflammatory bowel diseases (ulcerative colitis and Crohn's disease), a large, multibillion-dollar market where many therapies are administered via subcutaneous injections or intravenously, making an oral option particularly attractive, all else being equal